P904: Appendectomy for refractory ulcerative colitis: results of prospective observational studyECCO'24Year: 2024
Authors: Adamou, A.(1)*;Bercher, M.(1);Iesalnieks, I.(1);Streetz, K.(2);Morgenstern, J.(2);Dinter, J.(2);Bästlein, C.(3);Weingärtner, J.H.(3);
(1)Evangelisches Krankenhaus Kalk Cologne, Surgery, Cologne, Germany;(2)Evangelisches Krankenhaus Kalk Cologne, Gastroenterology, Cologne, Germany;(3)MDZ Wiener Platz, Gastroenterology, Cologne, Germany;
P905: Symptomatic remission and IUS improvements in a multi-national real-world cohort of UC patients treated with Upadacitinib - First results from the IBD-DACH study EUROPEECCO'24Year: 2024
Authors: Zeissig, S.(1)*;Schmelz, R.(1);Helwig, U.(2,3);Moschen, A.R.(4);Greuter, T.(5);Fischer, I.(6);Hammer, L.(7);Rath, S.(8);Kucharzik, T.(9);Maaser, C.(10);
(1)Technische Universität TU Dresden, Department of Medicine I and Center for Regenerative Therapies Dresden, Dresden, Germany;(2)Gastroenterology, Gastroenterology Practice Oldenburg, Oldenburg, Germany;(3)University of Kiel, University of Kiel, Kiel, Germany;(4)Johannes Kepler University of Linz, Department of Internal Medicine 2, Linz, Austria;(5)GZO AG Spital Wetzikon, Department of Gastroenterology, Wetzikon, Switzerland;(6)Biostatistik Tübingen, Biostatistik Tübingen, Tübingen, Germany;(7)AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany;(8)AbbVie Germany GmbH & Co. KG, Medical Department, Wiesbaden, Germany;(9)University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany;(10)University Teaching Hospital Lueneburg, Outpatients Department Gastroenterology, Lueneburg, Germany;IBD-DACH study group
P907: Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s Disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysisECCO'24Year: 2024
Authors: Fady, D.(1)*;El Kouzi, Z.(1);Ibrahim, M.A.(1);El Sheikh, W.(2);Khalife, M.(3);Tamim, H.(4);
(1)American University of Beirut, Gastroenterology, Beirut, Lebanon;(2)American University of Beirut, Medicine and Health Science, Beirut, Lebanon;(3)American University of Beirut, Surgery, Beirut, Lebanon;(4)American University of Beirut, Internal Medicine Biostatistics, Beirut, Lebanon;
P908: Real-life effectiveness and safety of tofacitinib and vedolizumab as a second-line therapy in anti-TNFs experienced patients ulcerative colitis: preliminary results of an IGIBD study (VE2TO-UC)ECCO'24Year: 2024
Authors: Noviello, D.(1)*;Savarino, E.(2);Fries, W.(3);Fantini, M.C.(4);Conforti, F.(5);Orlando, A.(6);Ribaldone, D.G.(7);Mocci, G.(8);Viganò, C.(9);Festa, S.(10);Spagnuolo, R.(11);Campigotto, M.(12);Grossi, L.(13);Gravina, A.G.(14);Principi, M.(15);Imperatore, N.(16);Carvalhas, A.(17);Scardino, G.(18);Scaldaferri, F.(19);Ceccarelli, L.(20);Biancone, L.(21);Di Sario, A.(22);De Barba, C.(2);De Francesco, C.(3);Calderone, S.(6);Onali, S.(4);Vecchi, M.(1);Ventimiglia, M.(23);Caprioli, F.(1);
(1)University of Milan, Department of Pathophysiology and Transplantation, Milano, Italy;(2)University of Padua, Department of Surgery- Oncology and Gastroenterology, Padova, Italy;(3)University of Messina, Dept. of Clinical and Experimental Medicine, Messina, Italy;(4)University of Cagliari, Department of Medical Sciences and Public Health, Cagliari, Italy;(5)Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milano, Italy;(6)@D@Villa Sofia-Cervello@D@ Hospital, Inflammatory bowel disease Unit, Palermo, Italy;(7)University of Turin, Department of Medical Sciences, Torino, Italy;(8)Azienda Ospedaliera ARNAS G. Brotzu, SC Gastroenterologia, Cagliari, Italy;(9)Division of Gastroenterology- Center for Autoimmune Liver Diseases- Department of Medicine and Surgery- University of Milano-Bicocca, European Reference Network on Hepatological Diseases ERN RARE-LIVER- Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy;(10)@D@San Filippo Neri@D@ Hospital, IBD Unit, Roma, Italy;(11)@D@Magna Graecia@D@ University, Department of Experimental Medicine and Clinic, Catanzaro, Italy;(12)ASUGI- Ospedale di Cattinara, Gastroenterologia ed Endoscopia Digestiva, Trieste, Italy;(13)@D@G d@E@Annunzio@D@ University, Gastroenterology Unit- @D@Spirito Santo@D@ Hospital, Pescara, Italy;(14)University of Campania Luigi Vanvitelli, Department of Precision Medicine- Hepatogastroenterology Unit, Napoli, Italy;(15)University of Bari, Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J- Gastroenterology Unit, Bari, Italy;(16)Gastroenterology and Endoscopy Unit, Santa Maria delle Grazie Hospital, Napoli, Italy;(17)ASST Fatebenefratelli-Sacco- Milano, Gastroenterology and Endoscopy Unit, Milano, Italy;(18)@D@Valduce@D@ Hospital, Gastroenterology Department, Como, Italy;(19)Fondazione Policlinico Universitario @D@A. Gemelli@D@ IRCCS- IBD Unit- CEMAD- Digestive Diseases Center- Medicina Interna e Gastroenterologia, Dipartimento di medicina e chirurgia Traslazionale - Università cattolica del Sacro Cuore- Roma, Roma, Italy;(20)Azienda Ospedaliero Universitaria Pisana, Gastroenterology Unit, Pisa, Italy;(21)University @E@Tor Vergata@E@ of Rome, Department of Systems Medicine, Roma, Italy;(22)Polytechnic Marche University, Department of Gastroenterology and Transplantation, Ancona, Italy;(23)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service, Roma, Italy;
P909: Proactive therapeutic drug monitoring and pharmacogenomics in mercaptopurine therapy for ulcerative colitisECCO'24Year: 2024
Authors: AnjieMD, S.(1)*;Derijks, L.J.(2);Volkers, A.G.(1);van Gennep, S.(1);Clasquin, E.(1);Duijvestein, M.(3);van Bodegraven, A.A.(4);Rietdijk, S.(5);van Asseldonk, D.P.(6);van der Zanden, E.P.(7);Hettinga, J.(1);West, R.L.(8);D@E@Haens, G.R.A.M.(1);Löwenberg, M.(1);Schwab, M.(9);de Boer, N.K.(10);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Máxima Medical Centre, Department of Clinical Pharmacy and Pharmacology, Veldhoven, The Netherlands;(3)Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(4)Zuyderland, Department of Gastroenterology and Hepatology, Sittard-Geleen, The Netherlands;(5)OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Noordwest Ziekenhuisgroep, Department of Gastroenterology and Hepatology, Alkmaar, The Netherlands;(7)Ziekenhuis Amstelland, Department of Gastroenterology and Hepatology, Amstelveen, The Netherlands;(8)Franciscus Gasthuis, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(9)Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Departments of Clinical Pharmacology- and Pharmacy and Biochemistry, Tuebingen, Germany;(10)Amsterdam Gastroenterology Endocrinology Metabolism Research Institute- Amsterdam University Medical Centre- Vrije Universiteit Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P910: Salivary calprotectin as a prognostic biomarker in Early Onset Inflammatory Bowel Disease: a cohort studyECCO'24Year: 2024
Authors: Liguori, S.(1)*;Musella, G.(1);Coppola , N.(1);Adamo, D.(1);Cantile, T.(1);Spagnuolo , G.(1);Del Giudice, C.(1);Miele, E.(2);Staiano, A.(2);Mignogna, M.D.(1);Leuci, S.(1);
(1)University of Naples Federico II, Department of Neurosciences- Reproductive and Odontostomatological Sciences, Naples, Italy;(2)University of Naples Federico II, Department of Translational Medical Science, Naples, Italy;
P911: Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBDECCO'24Year: 2024
Authors: Zhu, E.(1);Rios, D.(2);Milligan, J.(3);Ministro, J.(4);Friedman, J.(5)*;Nguyen, D.(6);Spencer, A.(7);Oh, J.(2);Shaheen, H.(8);
(1)Paragon Therapeutics, Biotherapeutics Discovery, Waltham- MA, United States;(2)Paragon Therapeutics, Biology, Waltham- MA, United States;(3)Paragon Therapeutics, Biotheapeutics Discovery, Waltham- MA, United States;(4)Paragon Therapeutics, Project Management, Waltham- MA, United States;(5)Spyre Therapeutics, Clinical Development, Ardmore, United States;(6)Spyre Therapeutics, Clinical Development, Waltham- MA, United States;(7)Spyre Therapeutics, Non-clinical Development, Waltham- MA, United States;(8)Paragon Therapeutics, Research, Waltham- MA, United States;
P912: A Real-World Evidence Study of Dose Escalation and associated costs of advanced therapies for Ulcerative Colitis in France and United KingdomECCO'24Year: 2024
Authors: Treuer, T.(1)*;Richards, M.(1);Mert, C.(2);Dhesi, E.(1);Silva, L.(3);Tan, Y.(4);Hoque, S.(5);
(1)Eli Lilly and Company, Eli Lilly and Company, Indianapolis, United States;(2)HaaPACS, GmbH, Schriesheim, Germany;(3)RWE, TFS HealthScience, Madrid, Spain;(4)Biostatistics, TFS HealthScience, Toronto, Canada;(5)Barts Health, NHS Trust, London, United Kingdom;
P913: Intestinal Ultrasound in paediatric Crohn’s disease reduces the need for subsequent ileocolonoscopyECCO'24Year: 2024
Authors: Dorn-Rasmussen, M.(1,2)*;Boysen, T.(2,3);Jakobsen, C.(1,2);Wewer, V.(1,2);
(1)Copenhagen University Hospital- Amager and Hvidovre, Department of Paediatric and Adolescence Medicine, Hvidovre, Denmark;(2)Copenhagen University Hospital- Amager and Hvidovre, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(3)Copenhagen University Hospital- Amager and Hvidovre, Gastrounit- Medical Division, Hvidovre, Denmark;
P916: Off-label dose escalation of Ustekinumab in Inflammatory Bowel Disease patients. Incidence rate, timing, dosing patterns and outcomes.ECCO'24Year: 2024
Authors: García-Morales, N.(1,2);Carmona, A.(3);Ayude, M.(1,2);Gayoso-Rey, M.(4);Agra-Blanco, I.(4);De Castro Parga, M.L.(1,2)*;Rodriguez-Prada, I.(1,2);
(1)Hospital Alvaro Cunqueiro CHUVI, Department of Gastroenterology, Vigo, Spain;(2)Galicia Sur Health Research Institute IIS Galicia Sur. SERGAS-UVIGO., Gastroenterology Research Group, Vigo, Spain;(3)Hospital Ribera-POVISA, Department of Gastroenterology, Vigo, Spain;(4)Hospital Alvaro Cunqueiro CHUVI, Department of Pharmacy, Vigo, Spain;
P917: Ustekinumab and immunomodulatory combination therapy is more effective than Ustekinumab monotherapy to prevent relapse in Crohn’s patients classified as low to intermediate-probability responders by UST-CDSTECCO'24Year: 2024
Authors: Song, J.H.(1)*;Shin, J.(2);Seong, G.(3);Kong, S.M.(4);Cha, B.(2);Hong , J.T.(2);Kwon, K.S.(2);
(1)Konkuk University Medical center, Internal medicine, Seoul, Korea- Republic Of;(2)Inha University Hospital, Internal Medicine, Incheon, Korea- Republic Of;(3)Eulji University Scool of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(4)Samsung Changwon Hospital, Medicine, Chagnwon, Korea- Republic Of;
P918: Can we rely on HLA to predict resistance to biological therapy in Inflammatory Bowel Disease patients?ECCO'24Year: 2024
Authors: Domingues, Â.(1);Carvalho, A.(1);Martinho, A.(2);Araújo, R.(1);Silva, A.(1);Ministro, P.(1)*;
(1)Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal;(2)Portuguese Institute of Blood and Transplantation, Blood and Transplantation, Coimbra, Portugal;
P919: Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patientsECCO'24Year: 2024
Authors: Scarallo, L.(1)*;Pochesci, S.(1);Fioretti, L.(1);Paci, M.(1);Renzo, S.(1);Naldini, S.(1);Lacitignola, L.(1);Barp, J.(1);Banci, E.(2);De Blasi, A.(1);Lionetti, P.(1);
(1)Meyer Children Hospital IRCCS, Gastroenterology and Nutrition Unit, Florence, Italy;(2)Meyer Children Hospital IRCCS, Dietetics Unit, Florence, Italy;
P920: Efficacy and Drug Adherence Rates of Anti TNF Drugs in patients with Crohn@E@s Disease: A Single Tertiary IBD Center CohortECCO'24Year: 2024
Authors: Eroglu, Z.(1);Yilmaz, V.(2)*;Guvenir, T.(2);Er, R.E.(2);Toruner, M.(3);
(1)Ankara University School of Medicine, Department of Internal Medicine, Ankara, Turkey;(2)Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey;(3)Ankara University Medical School- Ibni-sina Hospital, Department of Gastroenterology, Ankara, Turkey;
P921: Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab.ECCO'24Year: 2024
Authors: Piazza O Sed, N.(1)*;Maregatti, M.C.(2);Pessarelli, T.(2);Viganò , C.(3);Conforti, F.(1);Noviello, D.(2);Bezzio, C.(4);Amoroso, C.(1);Molteni, C.(2);Anolli, M.P.(2);Pirola, L.(3);Saibeni, S.(4);Fraquelli, M.(1);Vecchi, M.(2);Caprioli, F.(2);
(1)Foundation IRCCS Ca@E@ Granda Ospedale Maggiore Policlinico - Milan- Italy, Division of Gastroenterology and Endoscopy, Milan, Italy;(2)University of Milan- Milan Italy, Department of Pathophysiology and Transplantation, Milan, Italy;(3)European Reference Network on Hepatological Diseases ERN RARE-LIVER- Fondazione IRCCS San Gerardo dei Tintori- Monza- Italia, Division of Gastroenterology- Center for Autoimmune Liver Diseases- Department of Medicine and Surgery- University of Milano-Bicocca- Monza- Italy., Monza, Italy;(4)Rho Hospital- ASST Rhodense- Rho- Milan- Italy, Division of Gastroenterology, Rho- Milan, Italy;
P922: A multicenter retrospective real-world study to determine the optimal cases of vedolizumab-treated UC patients.ECCO'24Year: 2024
Authors: Kobayashi, T.(1)*;Hisamatsu, T.(2);Ishiguro, K.(3);Hirose, L.(3);Hibi, T.(1);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(3)Takeda Pharmaceutical Company Limited, Japan medical office, tokyo, Japan;
P923: Haematological abnormalities during treatment with Janus kinase inhibitors in patients with Ulcerative Colitis: a post hoc analysisECCO'24Year: 2024
Authors: Loveikyte , R.(1,2)*;Voorneveld , P.W.(1);Dijkstra , G.(2);van der Meulen - de Jong , A.E.(1);
(1)Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands;(2)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;
